Phase III Trial Opens: REVITALIZE Telehealth Intervention vs Educational Materials for PARP Inhibitor-Related Fatigue in Advanced Ovarian Cancer

References

1. 1.Bower, J. E. (2014). Cancer-related fatigue—mechanisms, risk factors, and treatments. Nature Reviews Clinical Oncology, 11(10), 597-609. https://doi.org/10.1038/nrclinonc.2014.127
2. 2.Dana-Farber Cancer Institute. (2024). Randomized Trial of REVITALIZE: A Telehealth Intervention to Reduce Fatigue Interference Among Adults With Advanced Ovarian Cancer on PARP Inhibitors. ClinicalTrials.gov. NCT06710548. https://clinicaltrials.gov/study/NCT06710548
3. 3.Hann, D. M., Jacobsen, P. B., Azzarello, L. M., Martin, S. C., Curran, S. L., Fields, K. K., Greenberg, H., & Lyman, G. (1998). Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory. Quality of Life Research, 7(4), 301-310. https://doi.org/10.1023/A:1008842517972
4. 4.LaFargue, C. J., Dal Molin, G. Z., Sood, A. K., & Coleman, R. L. (2019). Exploring and comparing adverse events between PARP inhibitors. The Lancet Oncology, 20(1), e15-e28. https://doi.org/10.1016/S1470-2045(18)30786-1
5. 5.Moore, K., Colombo, N., Scambia, G., Kim, B. G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., Gourley, C., Banerjee, S., Oza, A., González-Martín, A., Aghajanian, C., Bradley, W., Mathews, C., Liu, J., Lowe, E. S., Bloomfield, R., & DiSilvestro, P. (2018). Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine, 379(26), 2495-2505. https://doi.org/10.1056/NEJMoa1810858
6. 6.Pharmaceutical Benefits Scheme. (2024). PARP inhibitors - PBS listings. Australian Government Department of Health. https://www.pbs.gov.au/medicine/item/12849B
7. 7.Poveda, A., Floquet, A., Ledermann, J. A., Asher, R., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Pignata, S., Friedlander, M., Baldoni, A., Park-Simon, T. W., Tamura, K., Castonguay, V., Vulsteke, C., Graybill, W., Selle, F., Mirza, M. R., Shirinkin, V., ... Friedlander, M. (2021). Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology, 22(5), 620-631. https://doi.org/10.1016/S1470-2045(21)00073-5